54
Participants
Start Date
March 15, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
Bevacizumab； HRS-1167
Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
NOT_YET_RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
NOT_YET_RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Liaoning Cancer Hospital, Shenyang
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
First Affiliated Hospital of University of Science and Technology of China, Hefei
NOT_YET_RECRUITING
Qilu Hospital of Shandong University, Jinan
NOT_YET_RECRUITING
Shandong First Medical University Affiliated Cancer Hospital, Jinan
NOT_YET_RECRUITING
Tianjin Cancer Hospital, Tianjin
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
Chongqing University Cancer Hospital, Chongqing
NOT_YET_RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan
NOT_YET_RECRUITING
Guangxi Medical University Affiliated Tumor Hospital, Nanning
NOT_YET_RECRUITING
Sichuan Cancer Hospital, Chengdu
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
NOT_YET_RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiazhuang
NOT_YET_RECRUITING
Shanxi Provincial Cancer Hospital, Taiyuan
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY